AnaptysBio (NASDAQ:ANAB)‘s stock had its “buy” rating reissued by stock analysts at Robert W. Baird in a research note issued to investors on Friday. They currently have a $144.00 target price on the biotechnology company’s stock, up from their prior target price of $81.00. Robert W. Baird’s price objective suggests a potential upside of 25.32% from the stock’s current price.
Several other brokerages also recently weighed in on ANAB. Zacks Investment Research downgraded AnaptysBio from a “buy” rating to a “hold” rating in a research note on Tuesday, January 2nd. Royal Bank of Canada lifted their target price on AnaptysBio to $108.00 and gave the company an “outperform” rating in a research note on Monday, December 18th. SunTrust Banks began coverage on AnaptysBio in a research note on Wednesday, November 15th. They set a “buy” rating and a $115.00 target price on the stock. Credit Suisse Group lifted their target price on AnaptysBio from $38.00 to $85.00 and gave the company an “outperform” rating in a research note on Tuesday, October 10th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $76.00 target price (up previously from $35.00) on shares of AnaptysBio in a research note on Friday, October 13th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $96.33.
Shares of AnaptysBio (NASDAQ ANAB) opened at $114.91 on Friday. AnaptysBio has a 1-year low of $15.17 and a 1-year high of $116.67. The company has a current ratio of 10.77, a quick ratio of 10.77 and a debt-to-equity ratio of 0.09.
AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.02. analysts predict that AnaptysBio will post -1.72 EPS for the current year.
Institutional investors have recently made changes to their positions in the business. Evercore Wealth Management LLC bought a new stake in AnaptysBio during the 3rd quarter valued at $100,000. Legal & General Group Plc raised its stake in shares of AnaptysBio by 160.8% in the 3rd quarter. Legal & General Group Plc now owns 3,164 shares of the biotechnology company’s stock worth $110,000 after buying an additional 1,951 shares in the last quarter. DAFNA Capital Management LLC raised its stake in shares of AnaptysBio by 22.2% in the 2nd quarter. DAFNA Capital Management LLC now owns 5,500 shares of the biotechnology company’s stock worth $132,000 after buying an additional 1,000 shares in the last quarter. Nationwide Fund Advisors raised its stake in shares of AnaptysBio by 89.5% in the 3rd quarter. Nationwide Fund Advisors now owns 5,878 shares of the biotechnology company’s stock worth $205,000 after buying an additional 2,776 shares in the last quarter. Finally, New York State Common Retirement Fund bought a new stake in shares of AnaptysBio in the 2nd quarter worth $168,000. 75.48% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “AnaptysBio (ANAB) Stock Rating Reaffirmed by Robert W. Baird” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/21/anaptysbio-anab-stock-rating-reaffirmed-by-robert-w-baird.html.
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.